Edition:
United States

Antares Pharma Inc (ATRS.OQ)

ATRS.OQ on NASDAQ Stock Exchange Capital Market

3.25USD
11:38am EDT
Change (% chg)

$-0.17 (-4.97%)
Prev Close
$3.42
Open
$3.45
Day's High
$3.45
Day's Low
$3.22
Volume
164,653
Avg. Vol
199,868
52-wk High
$4.09
52-wk Low
$1.59

Chart for

About

Antares Pharma, Inc. (Antares) is a specialty pharmaceutical company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures pressure-assisted injector devices, with and without needles, which allow patients to self-inject drugs.... (more)
No analyst recommendations are available for .

Overall

Beta: 0.28
Market Cap(Mil.): €457.43
Shares Outstanding(Mil.): 157.44
Dividend: --
Yield (%): --

Financials

  ATRS.OQ Industry Sector
P/E (TTM): -- 39.75 32.94
EPS (TTM): -2.94 -- --
ROI: -- 14.12 12.84
ROE: -- 17.34 14.95

MEDIA-Russia to supply U.S. with new rocket engines - Kommersant

* Russian engine maker Energomash has signed a new contract to supply four RD-181 rocket engines to U.S. aerospace firm Orbital ATK by 2021 for its Antares rocket, the Kommersant newspaper wrote on Tuesday.

Sep 04 2018

BRIEF-Antares Pharma Reports Q1 Loss Per Share Of $0.04

* ANTARES PHARMA REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

May 08 2018

BRIEF-Antares Pharma Says FDA Accepts Resubmission To CRL For Xyosted NDA

* ANNOUNCED FDA ACKNOWLEDGED RECEIPT OF RESUBMISSION TO CRL RECEIVED IN CONNECTION WITH XYOSTED NEW DRUG APPLICATION

Apr 05 2018

BRIEF-Antares Pharma Provides Xyosted™ Regulatory Update

* BELIEVES THAT IT DOES NOT NEED TO CONDUCT ANY NEW CLINICAL STUDIES TO SUPPORT RESUBMISSION

Mar 27 2018

Earnings vs. Estimates

No consensus analysis data available.